世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000040293

融合生検市場-2029年までの世界予測

MarketsandMarkets

Fusion Biopsy Market - Global Forecast to 2029

発刊日 2024/12

言語英語

体裁PDF

ライセンス/価格

0000040293

Single
5-user
Corporate
Global

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

融合生検市場:ルートタイプ別 (経直腸、経会陰)、製品別 (機器、消耗品)、用途別 (前立腺がん)、エンドユーザー別 (病院)、地域別 - 2029年までの予測

融合生検市場は、2024年の6億5000万ドルから2029年には9億1000万ドルに成長し、予測期間中にCAGRは7.1%になると予想されています。市場の著名なプレーヤーには、Koninklijke Philips N.V.(オランダ)、GE Healthcare (米国)、KOELIS (フランス)、富士フイルムホールディングス (日本)、Eigen Health (米国)、Focal Healthcare (カナダ)、Esaote SPA (イタリア)、MTT GmbH (ドイツ)、MedCom (ドイツ)、UC-CARE Medical Systems (米国)、Biobot Surgical (シンガポール)、キヤノン株式会社 (日本)、Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (中国) が含まれます。

レポート詳細

目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
2.1.2.4 Breakdown of primary interviews
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 GROWTH RATE ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.7.2 SCOPE-RELATED LIMITATIONS
2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 FUSION BIOPSY MARKET OVERVIEW
4.2 NORTH AMERICA: FUSION BIOPSY MARKET, BY APPLICATION AND COUNTRY (2023)
4.3 FUSION BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 FUSION BIOPSY MARKET: REGIONAL MIX (2024-2029)
4.5 FUSION BIOPSY MARKET: DEVELOPED VS. DEVELOPING MARKETS

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of prostate cancer and growing geriatric population
5.2.1.2 Availability of reimbursements and investments by public and private sectors
5.2.1.3 Rising prevalence of minimally invasive surgery
5.2.2 RESTRAINTS
5.2.2.1 High costs of fusion biopsy systems
5.2.2.2 Alternative methods for fusion biopsy
5.2.3 OPPORTUNITIES
5.2.3.1 Rise in prevalence of prostate cancer in emerging economies
5.2.3.2 Technological advancements in fusion biopsy devices
5.2.4 CHALLENGES
5.2.4.1 Paucity of skilled professionals
5.2.4.2 Limited reimbursement in few countries
5.3 PRICING ANALYSIS
5.3.1 PRICING ANALYSIS, BY REGION
5.3.2 PRICING ANALYSIS, BY PRODUCT
5.4 VALUE CHAIN ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.6.1 FUSION BIOPSY MARKET: ROLE OF COMPANIES IN ECOSYSTEM
5.7 PORTER'S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 THREAT OF SUBSTITUTES
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 BARGAINING POWER OF SUPPLIERS
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.8.2 BUYING CRITERIA
5.9 REGULATORY LANDSCAPE
5.9.1 NORTH AMERICA
5.9.1.1 US
5.9.1.2 Canada
5.9.2 EUROPE
5.9.3 ASIA PACIFIC
5.9.3.1 Japan
5.9.3.2 China
5.9.3.3 India
5.9.4 LATIN AMERICA
5.9.4.1 BRAZIL
5.9.4.2 MEXICO
5.9.5 MIDDLE EAST
5.9.6 AFRICA
5.9.7 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10 TRADE ANALYSIS
5.10.1 TRADE ANALYSIS FOR FUSION BIOPSY MARKET
5.11 PATENT ANALYSIS
5.12 KEY CONFERENCES AND EVENTS IN 2024-2026
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.14 TECHNOLOGY ANALYSIS
5.14.1 KEY TECHNOLOGIES
5.14.1.1 MRI-ultrasound fusion imaging
5.14.2 COMPLEMENTARY TECHNOLOGIES
5.14.2.1 Liquid biopsy
5.14.2.1.1 Digital droplet PCR
5.14.2.1.2 Tagged-amplicon deep sequencing
5.15 INVESTMENT & FUNDING SCENARIO
5.16 IMPACT OF GENERATIVE ARTIFICIAL INTELLIGENCE ON FUSION BIOPSY MARKET

6 FUSION BIOPSY MARKET, BY ROUTE TYPE
6.1 INTRODUCTION
6.2 TRANSRECTAL
6.2.1 HEIGHTENED POTENTIAL FOR SERIOUS INFECTIONS TO HINDER MARKET GROWTH
6.3 TRANSPERINEAL
6.3.1 IMPROVED CANCER DETECTION THROUGH COMBINATION OF MRI AND ULTRASOUND TO FUEL MARKET GROWTH
6.4 OTHER ROUTE TYPES

7 FUSION BIOPSY MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 PROSTATE CANCER
7.2.1 PRECISE AND RELIABLE RESULTS OF PROSTATE FUSION BIOPSY TO ACCELERATE MARKET GROWTH
7.3 OTHER APPLICATIONS

8 FUSION BIOPSY MARKET, BY PRODUCT
8.1 INTRODUCTION
8.2 EQUIPMENT
8.2.1 SUBSTANTIAL INITIAL INVESTMENTS TO ENSURE MARKET GROWTH
8.3 CONSUMABLES
8.3.1 INCREASING APPLICATION OF INNOVATIVE TECHNOLOGIES AND METHODOLOGIES TO PROPEL MARKET GROWTH

9 FUSION BIOPSY MARKET, BY END USER
9.1 INTRODUCTION
9.2 HOSPITALS
9.2.1 RISING DEMAND FOR QUICK AND ACCURATE DIAGNOSIS TO PROMOTE MARKET GROWTH
9.3 OTHER END USERS

10 FUSION BIOPSY MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2 US
10.2.2.1 Funding for cancer research and availability of technologically advanced products to propel market growth
10.2.3 CANADA
10.2.3.1 Surging need for advanced diagnostic solutions to drive market
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2 GERMANY
10.3.2.1 Rising healthcare expenditure and increasing incidence of cancer to bolster market growth
10.3.3 UK
10.3.3.1 Enhanced clinical infrastructure to accelerate fusion biopsy adoption
10.3.4 FRANCE
10.3.4.1 Effective reimbursement policies and government support for surgical product manufacturers to augment market
10.3.5 ITALY
10.3.5.1 Rising healthcare demands of geriatric population to support market growth
10.3.6 SPAIN
10.3.6.1 Improved healthcare infrastructure and rising geriatric demographics to boost market
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2 CHINA
10.4.2.1 Increasing disposable income of middle-class population and rising diagnostic procedures to boost market
10.4.3 JAPAN
10.4.3.1 Robust healthcare system and surging need for precise early cancer detection to support market growth
10.4.4 INDIA
10.4.4.1 Large patient population and increasing healthcare investments to drive market
10.4.5 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 LOW FOCUS ON INFRASTRUCTURAL IMPROVEMENT AND POOR DISTRIBUTION OF RESOURCES LIKELY TO HINDER MARKET GROWTH
10.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA & CARIBBEAN
10.6 MIDDLE EAST & AFRICA
10.6.1 EXPANDING ACCESS TO HEALTHCARE AND INCREASED HEALTHCARE INVESTMENTS TO PROPEL MARKET
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
10.7 GCC COUNTRIES
10.7.1 ADVANCEMENTS AND INCREASED GOVERNMENT INVESTMENTS IN HEALTHCARE SECTOR TO PROPEL MARKET
10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN FUSION BIOPSY MARKET
11.3 REVENUE SHARE ANALYSIS, 2021-2023
11.4 MARKET SHARE ANALYSIS, 2023
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 Company footprint
11.5.5.2 Region footprint
11.5.5.3 Route type footprint
11.5.5.4 Product footprint
11.5.5.5 Application footprint
11.5.5.6 End user footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
11.7 COMPANY VALUATION & FINANCIAL METRICS, 2024
11.8 BRAND/PRODUCT COMPARISON
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES & APPROVALS
11.9.2 DEALS

12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 KONINKLIJKE PHILIPS N.V.
12.1.1.1 Business overview
12.1.1.2 Products offered
12.1.1.3 MnM view
12.1.1.3.1 Key strengths
12.1.1.3.2 Strategic choices
12.1.1.3.3 Weaknesses & competitive threats
12.1.2 GE HEALTHCARE
12.1.2.1 Business overview
12.1.2.2 Products offered
12.1.2.3 MnM view
12.1.2.3.1 Right to win
12.1.2.3.2 Strategic choices
12.1.2.3.3 Weaknesses & competitive threats
12.1.3 KOELIS
12.1.3.1 Business overview
12.1.3.2 Products offered
12.1.3.3 Recent developments
12.1.3.3.1 Deals
12.1.3.4 MnM view
12.1.3.4.1 Right to win
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses & competitive threats
12.1.4 FUJIFILM HOLDINGS CORPORATION
12.1.4.1 Business overview
12.1.4.2 Products offered
12.1.4.3 Recent developments
12.1.4.3.1 Product launches & approvals
12.1.5 CANON INC.
12.1.5.1 Business overview
12.1.5.2 Products offered
12.1.6 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
12.1.6.1 Business overview
12.1.6.2 Products offered
12.1.7 ESAOTE SPA
12.1.7.1 Business overview
12.1.7.2 Products offered
12.1.8 EIGEN HEALTH
12.1.8.1 Business overview
12.1.8.2 Products offered
12.2 OTHER PLAYERS
12.2.1 FOCAL HEALTHCARE
12.2.2 MTT GMBH
12.2.3 MEDCOM
12.2.4 UC-CARE MEDICAL SYSTEMS
12.2.5 BIOBOT SURGICAL

13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS

List of Tables
TABLE 1 RISK ASSESSMENT
TABLE 2 PROSTATE CANCER INCIDENCE, BY REGION, 2022
TABLE 3 AVERAGE SELLING PRICE TREND OF FUSION BIOPSY PRODUCTS, BY REGION, 2021-2023
TABLE 4 PRICING ANALYSIS OF FUSION BIOPSY PRODUCTS, 2021-2023
TABLE 5 FUSION BIOPSY MARKET: PORTER'S FIVE FORCES ANALYSIS
TABLE 6 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF FUSION BIOPSY END USERS (%)
TABLE 7 KEY BUYING CRITERIA FOR FUSION BIOPSY END USERS
TABLE 8 US FDA: MEDICAL DEVICE CLASSIFICATION
TABLE 9 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
TABLE 10 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
TABLE 11 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
TABLE 12 CHINA: CLASSIFICATION OF MEDICAL DEVICES
TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 IMPORT DATA FOR FUSION BIOPSY MARKET, BY COUNTRY, 2019-2023 (USD MILLION)
TABLE 19 EXPORT DATA FOR FUSION BIOPSY MARKET, BY COUNTRY, 2019-2023 (USD MILLION)
TABLE 20 FUSION BIOPSY MARKET: KEY CONFERENCES AND EVENTS IN 2024-2026
TABLE 21 FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
TABLE 22 FUSION BIOPSY MARKET FOR TRANSRECTAL ROUTE TYPES, BY REGION, 2022-2029 (USD MILLION)
TABLE 23 NORTH AMERICA: FUSION BIOPSY MARKET FOR TRANSRECTAL ROUTE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 24 EUROPE: FUSION BIOPSY MARKET FOR TRANSRECTAL ROUTE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC: FUSION BIOPSY MARKET FOR TRANSRECTAL ROUTE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 26 FUSION BIOPSY MARKET FOR TRANSPERINEAL ROUTE TYPES, BY REGION, 2022-2029 (USD MILLION)
TABLE 27 NORTH AMERICA: FUSION BIOPSY MARKET FOR TRANSPERINEAL ROUTE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 28 EUROPE: FUSION BIOPSY MARKET FOR TRANSPERINEAL ROUTE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC: FUSION BIOPSY MARKET FOR TRANSPERINEAL ROUTE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 30 FUSION BIOPSY MARKET FOR OTHER ROUTE TYPES, BY REGION, 2022-2029 (USD MILLION)
TABLE 31 NORTH AMERICA: FUSION BIOPSY MARKET FOR OTHER ROUTE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 32 EUROPE: FUSION BIOPSY MARKET FOR OTHER ROUTE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 33 ASIA PACIFIC: FUSION BIOPSY MARKET FOR OTHER ROUTE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 34 FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 35 PROSTATE CANCER INCIDENCE, BY REGION, 2022
TABLE 36 FUSION BIOPSY MARKET FOR PROSTATE CANCER, BY REGION, 2022-2029 (USD MILLION)
TABLE 37 NORTH AMERICA: FUSION BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 38 EUROPE: FUSION BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 39 ASIA PACIFIC: FUSION BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 40 FUSION BIOPSY MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
TABLE 41 NORTH AMERICA: FUSION BIOPSY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 42 EUROPE: FUSION BIOPSY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 43 ASIA PACIFIC: FUSION BIOPSY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 44 FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 45 KEY PRODUCTS IN FUSION BIOPSY EQUIPMENT MARKET
TABLE 46 FUSION BIOPSY MARKET FOR EQUIPMENT, BY REGION, 2022-2029 (USD MILLION)
TABLE 47 NORTH AMERICA: FUSION BIOPSY MARKET FOR EQUIPMENT, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 48 EUROPE: FUSION BIOPSY MARKET FOR EQUIPMENT, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 49 ASIA PACIFIC: FUSION BIOPSY MARKET FOR EQUIPMENT, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 50 KEY PRODUCTS IN FUSION BIOPSY CONSUMABLES MARKET
TABLE 51 FUSION BIOPSY MARKET FOR CONSUMABLES, BY REGION, 2022-2029 (USD MILLION)
TABLE 52 NORTH AMERICA: FUSION BIOPSY MARKET FOR CONSUMABLES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 53 EUROPE: FUSION BIOPSY MARKET FOR CONSUMABLES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 54 ASIA PACIFIC: FUSION BIOPSY MARKET FOR CONSUMABLES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 55 FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 56 FUSION BIOPSY MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD MILLION)
TABLE 57 NORTH AMERICA: FUSION BIOPSY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 58 EUROPE: FUSION BIOPSY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 59 ASIA PACIFIC: FUSION BIOPSY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 60 FUSION BIOPSY MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 61 NORTH AMERICA: FUSION BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 62 EUROPE: FUSION BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 63 ASIA PACIFIC: FUSION BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 64 FUSION BIOPSY MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 65 NORTH AMERICA: PROSTATE CANCER INCIDENCE, BY COUNTRY, 2022
TABLE 66 NORTH AMERICA: MACROECONOMIC OUTLOOK
TABLE 67 NORTH AMERICA: FUSION BIOPSY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 68 NORTH AMERICA: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
TABLE 69 NORTH AMERICA: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 70 NORTH AMERICA: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 71 NORTH AMERICA: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 72 US: NUMBER OF MAGNETIC RESONANCE IMAGING (MRI) EXAMS CONDUCTED, 2022-2029 (NUMBER PER 1,000 PERSONS)
TABLE 73 US: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
TABLE 74 US: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 75 US: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 76 US: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 77 CANADA: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
TABLE 78 CANADA: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 79 CANADA: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 80 CANADA: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 81 EUROPE: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
TABLE 82 EUROPE: MACROECONOMIC OUTLOOK
TABLE 83 EUROPE: FUSION BIOPSY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 84 EUROPE: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
TABLE 85 EUROPE: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 86 EUROPE: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 87 EUROPE: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 88 GERMANY: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
TABLE 89 GERMANY: NUMBER OF MAGNETIC RESONANCE IMAGING (MRI) EXAMS CONDUCTED, 2022-2029 (NUMBER PER 1,000 PERSONS)
TABLE 90 GERMANY: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
TABLE 91 GERMANY: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 92 GERMANY: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 93 GERMANY: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 94 UK: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
TABLE 95 UK: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
TABLE 96 UK: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 97 UK: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 98 UK: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 99 FRANCE: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
TABLE 100 FRANCE: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
TABLE 101 FRANCE: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 102 FRANCE: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 103 FRANCE: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 104 ITALY: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
TABLE 105 ITALY: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
TABLE 106 ITALY: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 107 ITALY: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 108 ITALY: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 109 SPAIN: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
TABLE 110 SPAIN: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
TABLE 111 SPAIN: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 112 SPAIN: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 113 SPAIN: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 114 REST OF EUROPE: PROSTATE CANCER INCIDENCE, BY COUNTRY, 2022
TABLE 115 REST OF EUROPE: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
TABLE 116 REST OF EUROPE: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 117 REST OF EUROPE: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 118 REST OF EUROPE: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 119 ASIA PACIFIC: MACROECONOMIC OUTLOOK
TABLE 120 ASIA PACIFIC: FUSION BIOPSY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 121 ASIA PACIFIC: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
TABLE 122 ASIA PACIFIC: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 123 ASIA PACIFIC: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 124 ASIA PACIFIC: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 125 CHINA: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030
TABLE 126 CHINA: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
TABLE 127 CHINA: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 128 CHINA: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 129 CHINA: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 130 JAPAN: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030
TABLE 131 JAPAN: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
TABLE 132 JAPAN: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 133 JAPAN: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 134 JAPAN: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 135 INDIA: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030
TABLE 136 INDIA: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
TABLE 137 INDIA: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 138 INDIA: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 139 INDIA: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 140 PROSTATE CANCER INCIDENCE, BY COUNTRY, 2022 VS. 2030
TABLE 141 REST OF ASIA PACIFIC: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
TABLE 142 REST OF ASIA PACIFIC: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 143 REST OF ASIA PACIFIC: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 144 REST OF ASIA PACIFIC: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 145 LATIN AMERICA: PROSTATE CANCER INCIDENCE, 2022
TABLE 146 LATIN AMERICA & CARIBBEAN: MACROECONOMIC OUTLOOK
TABLE 147 LATIN AMERICA: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
TABLE 148 LATIN AMERICA: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 149 LATIN AMERICA: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 150 LATIN AMERICA: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 151 AFRICA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
TABLE 152 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
TABLE 153 MIDDLE EAST & AFRICA: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
TABLE 154 MIDDLE EAST & AFRICA: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 155 MIDDLE EAST & AFRICA: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 156 MIDDLE EAST & AFRICA: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 157 GCC COUNTRIES: MACROECONOMIC OUTLOOK
TABLE 158 GCC COUNTRIES: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
TABLE 159 GCC COUNTRIES: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 160 GCC COUNTRIES: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 161 GCC COUNTRIES: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 162 OVERVIEW OF STRATEGIES ADOPTED BY KEY MARKET PLAYERS
TABLE 163 FUSION BIOPSY MARKET: DEGREE OF COMPETITION
TABLE 164 FUSION BIOPSY MARKET: COMPANY FOOTPRINT
TABLE 165 FUSION BIOPSY MARKET: REGION FOOTPRINT
TABLE 166 FUSION BIOPSY MARKET: ROUTE TYPE FOOTPRINT
TABLE 167 FUSION BIOPSY MARKET: PRODUCT FOOTPRINT
TABLE 168 FUSION BIOPSY MARKET: APPLICATION FOOTPRINT
TABLE 169 FUSION BIOPSY MARKET: END USER FOOTPRINT
TABLE 170 FUSION BIOPSY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
TABLE 171 FUSION BIOPSY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
TABLE 172 FUSION BIOPSY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MARCH 2024
TABLE 173 FUSION BIOPSY MARKET: DEALS, JANUARY 2021-MARCH 2024
TABLE 174 KONINKLIJKE PHILIPS N.V.: BUSINESS OVERVIEW
TABLE 175 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED
TABLE 176 GE HEALTHCARE: BUSINESS OVERVIEW
TABLE 177 GE HEALTHCARE: PRODUCTS OFFERED
TABLE 178 KOELIS: BUSINESS OVERVIEW
TABLE 179 KOELIS: PRODUCT OFFERED
TABLE 180 KOELIS: DEALS, JANUARY 2021-MARCH 2024
TABLE 181 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
TABLE 182 FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED
TABLE 183 FUJIFILM HOLDINGS CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MARCH 2024
TABLE 184 CANON INC.: BUSINESS OVERVIEW
TABLE 185 CANON INC.: PRODUCTS OFFERED
TABLE 186 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: BUSINESS OVERVIEW
TABLE 187 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED
TABLE 188 ESAOTE SPA: BUSINESS OVERVIEW
TABLE 189 ESAOTE SPA: PRODUCTS OFFERED
TABLE 190 EIGEN HEALTH: COMPANY OVERVIEW
TABLE 191 EIGEN HEALTH: PRODUCTS OFFERED

List of Figures
FIGURE 1 FUSION BIOPSY MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2 FUSION BIOPSY MARKET: RESEARCH DESIGN
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 5 FUSION BIOPSY MARKET: REVENUE SHARE ANALYSIS
FIGURE 6 APPROACH BASED ON PATIENT POPULATION
FIGURE 7 APPROACH BASED ON NUMBER OF HOSPITALS
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 9 FUSION BIOPSY MARKET: TOP-DOWN APPROACH
FIGURE 10 DATA TRIANGULATION METHODOLOGY
FIGURE 11 FUSION BIOPSY MARKET, BY ROUTE TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 12 FUSION BIOPSY MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
FIGURE 13 FUSION BIOPSY MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 14 FUSION BIOPSY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF FUSION BIOPSY MARKET
FIGURE 16 INCREASING PREVALENCE OF PROSTATE CANCER TO DRIVE MARKET GROWTH
FIGURE 17 PROSTATE CANCER SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023
FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 19 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 20 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
FIGURE 21 FUSION BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 22 VALUE CHAIN ANALYSIS OF FUSION BIOPSY MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
FIGURE 23 FUSION BIOPSY MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 24 FUSION BIOPSY MARKET: ECOSYSTEM ANALYSIS
FIGURE 25 KEY PLAYERS IN FUSION BIOPSY MARKET ECOSYSTEM
FIGURE 26 FUSION BIOPSY MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF FUSION BIOPSY END USERS
FIGURE 28 KEY BUYING CRITERIA FOR FUSION BIOPSY END USERS
FIGURE 29 PATENT ANALYSIS FOR FUSION BIOPSY MARKET, JANUARY 2014-OCTOBER 2024
FIGURE 30 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS IN FUSION BIOPSY MARKET
FIGURE 31 FUSION BIOPSY MARKET: INVESTMENT & FUNDING SCENARIO
FIGURE 32 NORTH AMERICA: FUSION BIOPSY MARKET SNAPSHOT
FIGURE 33 ASIA PACIFIC: FUSION BIOPSY MARKET SNAPSHOT
FIGURE 34 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN FUSION BIOPSY MARKET, 2021-2023
FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN FUSION BIOPSY MARKET (2023)
FIGURE 36 FUSION BIOPSY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
FIGURE 37 FUSION BIOPSY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
FIGURE 38 EV/EBITDA OF KEY VENDORS, 2024
FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND FIVE-YEAR STOCK BETA OF KEY VENDORS
FIGURE 40 FUSION BIOPSY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 41 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023)
FIGURE 42 GE HEALTHCARE: COMPANY SNAPSHOT (2023)
FIGURE 43 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 44 CANON INC.: COMPANY SNAPSHOT (2023)
FIGURE 45 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2022)

この商品のレポートナンバー

0000040293

TOP